Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Eteplirsen · Exondys 51, AVI-4658

Oligonucleotide (Antisense oligonucleotide) · Gene silencing: dystrophin (DMD) pre-mRNA (DMD) · developed by Sarepta Theraps

Approved FDA, Sep 2016
SRPT Developer
5 Registered trials

What is Eteplirsen?

Eteplirsen is an antisense oligonucleotide that binds exon 51 of dystrophin pre-mRNA, causing that exon to be excluded during mRNA processing. It is intended to allow production of an internally truncated dystrophin protein in patients with mutations amenable to exon 51 skipping. It is studied in Duchenne muscular dystrophy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Exondys 51, AVI-4658, EXONDYS 51, EXONDYS
Drug type
Oligonucleotide (Antisense oligonucleotide)
Targets
dystrophin (DMD) pre-mRNA (DMD)
Mechanism
Gene silencing: dystrophin (DMD) pre-mRNA (DMD)
Pathways
exon skipping during dystrophin pre-mRNA processing, production of internally truncated dystrophin
Therapy area
Musculoskeletal, Neurology
Developer
Sarepta Theraps Inc (SRPT)
FDA status
Approved as Exondys 51 (September 19, 2016), NDA206488 · FDA label
UNII
AIW6036FAS

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 13, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03992430 Phase 3 Muscular Dystrophy, Duchenne Completed SRPT
NCT04179409 Phase 2 Duchenne Muscular Dystrophy Completed SRPT
NCT01540409 Phase 2 Duchenne Muscular Dystrophy (DMD) Completed SRPT
NCT00844597 Phase 1/2 Duchenne Muscular Dystrophy Completed SRPT
NCT00159250 Phase 1/2 Duchenne Muscular Dystrophy Completed SRPT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Duchenne Muscular DystrophyDuchenne Muscular Dystrophy (DMD)Muscular Dystrophy, Duchenne

Other drugs acting on DMD

More from Sarepta Theraps

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the SRPT page.

Follow SRPT, the company behind Eteplirsen

See SRPT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SRPT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.